1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea

ID: ALA273564

Chembl Id: CHEMBL273564

PubChem CID: 23646938

Max Phase: Preclinical

Molecular Formula: C20H14F3N5O2

Molecular Weight: 413.36

Molecule Type: Small molecule

Names and Identifiers

Synonyms: GW795493X | GW795493X|3-(4-{4-aminofuro[2,3-d]pyrimidin-5-yl}phenyl)-1-[3-(trifluoromethyl)phenyl]urea|CHEMBL273564|BDBM15006|LSVIBAPJYUUVJJ-UHFFFAOYSA-N|HMS3304L01|HMS3305H12|NSC756358|NSC-756358|NCGC00242246-01|4-amino-5-diarylurea-furo[2,3-d]pyrimidine 8d|AB01092338-01|1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea

Canonical SMILES:  Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12

Standard InChI:  InChI=1S/C20H14F3N5O2/c21-20(22,23)12-2-1-3-14(8-12)28-19(29)27-13-6-4-11(5-7-13)15-9-30-18-16(15)17(24)25-10-26-18/h1-10H,(H2,24,25,26)(H2,27,28,29)

Standard InChI Key:  LSVIBAPJYUUVJJ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA273564

   GW795493X

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 413.36

Molecular Weight (Monoisotopic): 413.1100

AlogP: 5.13

#Rotatable Bonds: 3

Polar Surface Area: 106.07

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.38

CX Basic pKa: 2.48

CX LogP: 4.01

CX LogD: 4.01

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.43

Np Likeness Score: -1.13

References

1. Miyazaki Y, Tang J, Maeda Y, Nakano M, Wang L, Nolte RT, Sato H, Sugai M, Okamoto Y, Truesdale AT, Hassler DF, Nartey EN, Patrick DR, Ho ML, Ozawa K..  (2007)  Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2.,  17  (6): [PMID:17276055] [10.1016/j.bmcl.2006.12.077]

2. PubChem BioAssay data set, 

3. Compounds: GSK PKIS; Assays: Nanosyn kinase panel,  [10.6019/CHEMBL1961873]

4. Compounds: GSK PKIS; Assays: UNC Frye lab,  [10.6019/CHEMBL2007661]

5. Data associated with the publication PLoS ONE, 8(3), e57888, (2013) PMID: 23505445. Compounds: GSK PKIS; Assays: NIH NCATS, 

6. Harris PA, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, Cox JA, Dare L, Finger JN, Hoffman SJ, Kahler KM, Lehr R, Lich JD, Nagilla R, Nolte RT, Ouellette MT, Pao CS, Schaeffer MC, Smallwood A, Sun HH, Swift BA, Totoritis RD, Ward P, Marquis RW, Bertin J, Gough PJ..  (2013)  Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis.,  4  (12): [PMID:24900635] [10.1021/ml400382p]

Source

Source(3):

• Scientific Literature
• PubChem BioAssays
• GSK Published Kinase Inhibitor Set